---
company: Hinge Health, Inc.
ticker: HNGE
form: 8-K
filed: 2026-08-04
accession: 0001628280-26-052558
source: https://www.sec.gov/Archives/edgar/data/1673743/000162828026052558/
---

# Hinge Health (HNGE) earnings release, August 4, 2026

Hinge Health, Inc. (HNGE) · Form 8-K, Item 2.02 · Filed 2026-08-04 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1673743/000162828026052558/)

Hinge Health reports record second quarter 2026 financial results; signs definitive agreement to acquire Cylinder Health

• Signed a definitive agreement to acquire Cylinder Health, Inc., expanding into gastrointestinal care

• Revenue increased 53% year-over-year to $213 million

• Free cash flow of $100 million, up 3x year-over-year

• 2026 revenue guidance midpoint raised to $858 million, reflecting 46% year-over-year growth

• Board approved a $300 million increase to the share repurchase program

San Francisco, California – August 4, 2026 – Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the second quarter ended June 30, 2026 and provided a business update.

“We delivered another strong quarter ahead of expectations, generating $213 million in revenue with 53% year-over-year growth, while more than tripling free cash flow from a year ago. This quarter’s outperformance was driven by continued high member conversion and reflects our ability to deliver a great experience, improve member outcomes and lower client costs,” said Daniel Perez, Co-Founder and CEO, Hinge Health. “We also announced the acquisition of Cylinder Health today, marking our entry into gastrointestinal (GI) care. Combined with the strength of our core musculoskeletal care programs and the rapid adoption of our Migraine Care Program, our expansion into GI is another step toward our vision of building a durable, multi-condition platform to automate the delivery of care. Building on this momentum, we're raising our revenue and profitability expectations for the remainder of 2026, and are confident in our trajectory for 2027.”

Second Quarter Financial Highlights:

• Revenue increased 53% year-over-year to $212.8 million compared to revenue of $139.1 million in Q2 2025.

• GAAP gross margin was 86% compared to 70% in Q2 2025.

Non-GAAP gross margin was 87% compared to 83% in Q2 2025.

• GAAP income from operations increased to $40.4 million compared to GAAP loss from operations of $580.7 million in Q2 2025, which included $591.0 million in stock-based compensation expense.

Non-GAAP income from operations increased 136% to $61.5 million compared to $26.1 million in Q2 2025.

• GAAP operating margin was 19% compared to (417)% in Q2 2025.

Non-GAAP operating margin was 29% compared to 19% in Q2 2025.

• GAAP diluted net income per share was $0.52 compared to a GAAP diluted net loss per share of $13.10 in Q2 2025.

Non-GAAP diluted net income per share was

$0.59 compared to $0.30 in Q2 2025.

• Net cash provided by operating activities increased to $101.4 million compared to $20.2 million in Q2 2025.

Free cash flow increased to $99.6 million compared to $32.6 million in Q2 2025.

• Cash, cash equivalents, marketable securities and restricted cash were $475.6 million as of June 30, 2026.¹

Company Highlights and Key Metrics:

• LTM calculated billings increased 52% year-over-year to $861.8 million as of June 30, 2026, compared to $568.4 million as of June 30, 2025.

• Number of clients increased 24% year-over-year to 2,929 clients as of June 30, 2026, compared to 2,359 clients as of June 30, 2025.

• Signed a definitive agreement to acquire Cylinder Health, Inc., a leader in virtual-first digestive healthcare, for $105 million in cash consideration. The acquisition will combine Cylinder Health’s clinical expertise and existing market footprint with Hinge Health’s AI-powered care model and technology platform to deliver support in a single app with an integrated Gastrointestinal Care Program, expected to launch in 2027. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2026.

Financial Outlook:

We are providing the following guidance for our third quarter 2026 and full year 2026:

• Q3 2026:

We expect revenue to be between $223 million and $225 million, reflecting year-over-year growth of 45% at the midpoint. We expect non-GAAP income from operations to be between $61 million and $63 million, reflecting year-over-year growth of 104% and non-GAAP operating margin of 28% at the midpoint.

• Full Year 2026:

We are raising our revenue guidance to be between $856 million and $860 million, reflecting year-over-year growth of 46% at the midpoint. We are raising our non-GAAP income from operations guidance to be between $236 million and $244 million, reflecting year-over-year growth of 101% and non-GAAP operating margin of 28% at the midpoint.

Share Repurchase Program

On November 10, 2025, our board of directors approved a share repurchase program with authorization to purchase up to $250 million of our Class A common stock. As of July 29, 2026, we had repurchased an aggregate of $196.5 million of our Class A common stock under the program. On July 29, 2026, our board of directors approved an increase to the program, resulting in $300.0 million of our Class A common stock available for future repurchase, for a total aggregate amount authorized under the program of $496.5 million as of such date.

Repurchases under the program may be made in the open market, in privately negotiated transactions or by other methods, with the amount, manner, price, and timing of repurchases to be determined at our discretion, depending on a variety of factors, including business,... (truncated)etion of our board of directors. We expect to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.

Statement Regarding Use of Non-GAAP Financial Measures

This press release uses non-GAAP financial measures, which are not calculated in accordance with generally accepted accounting principles of the United States (GAAP). For more information about these non-GAAP financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP, please see the “Non-GAAP Financial Measures” section below.²

Moreover, we have not reconciled our non-GAAP income from operations and non-GAAP operating margin guidance to GAAP income from operations and GAAP operating margin because we do not and are not able to provide guidance for GAAP income from operations due to the uncertainty and potential variability of stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and adjustments, such as acquisition-related expense, which are reconciling items between non-GAAP and GAAP income from operations and operating margin. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measures. However, such items could have a significant impact on our future GAAP income from operations.

Hinge Health Earnings Webcast

We will host a conference call and webcast for investors on August 4, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss our financial results, business highlights and financial outlook. The live webcast of the conference call can be accessed by registering online at ir.hingehealth.com/events-presentations. Following completion of the event, a webcast replay will also be available at ir.hingehealth.com for 12 months.

About Hinge Health

Hinge Health is focused on scaling and automating the delivery of health care. Leveraging an AI-powered care model, connected hardware and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that improves member outcomes and experiences while reducing costs for clients. The company is headquartered in San Francisco, California.

Available Information

Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including filings with the U.S. Securities and Exchange Commission (“SEC”), the investor relations page on our website (ir.hingehealth.com), press releases, public conference calls, and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our obligations under Regulation FD.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our proposed acquisition of Cylinder Health and the timing and anticipated benefits and synergies associated with the acquisition, statements regarding our expectations regarding our financial position and operating performance, including our outlook and guidance for the third quarter of 2026 and guidance for full year 2026 and our assumptions underlying such guidance; expectations regarding our share repurchase program; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including those more fully described in our filings with the SEC, including in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 3, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, when filed with the SEC. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.³

## Financial statements

### Income Statement (Three Months Ended June 30, — (in thousands, except per share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | 212,817 | 139,098 | 395,124 | 262,923 |
| Cost of revenue | 28,868 | 41,335 | 56,942 | 64,927 |
| Gross profit | 183,949 | 97,763 | 338,182 | 197,996 |
| Operating expenses: | Research and development | 34,057 | 279,962 | 64,395 | 303,462 |
| Operating expenses: | Sales and marketing | 81,408 | 147,228 | 150,210 | 193,944 |
| Operating expenses: | General and administrative | 28,044 | 251,244 | 51,068 | 268,125 |
| Operating expenses: | Total operating expenses | 143,509 | 678,434 | 265,673 | 765,531 |
| Operating expenses: | Income (loss) from operations | 40,440 | -580,671 | 72,509 | -567,535 |
| Other income: | Other income, net | 3,990 | 4,694 | 7,863 | 9,695 |
| Other income: | Net income (loss) before income taxes | 44,430 | -575,977 | 80,372 | -557,840 |
| Other income: | Provision for (benefit from) income taxes | 740 | -326 | 1,554 | 672 |
| Other income: | Net income (loss) | 43,690 | -575,651 | 78,818 | -558,512 |
| Other income: | Adjustment to reflect deemed contribution from Series D and Series E redeemable convertible preferred stock extinguishment |  |  |  | 104,174 |
| Other income: | Income allocated to participating securities | -588 |  | -1,784 |  |
| Other income: | Net income (loss) attributable to common stockholders, basic | 43,102 | -575,651 | 77,034 | -454,338 |
| Other income: | Net income (loss) attributable to common stockholders, diluted | 43,133 | -575,651 | 77,109 | -454,338 |
| Net income (loss) attributable to common stockholders per share: | Basic | 0.55 | -13.1 | 0.98 | -15.05 |
| Net income (loss) attributable to common stockholders per share: | Diluted | 0.52 | -13.1 | 0.94 | -15.05 |
| Weighted average shares used in computing net income (loss) per share attributable to common stockholders: | Basic | 78,969 | 43,931 | 78,795 | 30,190 |
| Weighted average shares used in computing net income (loss) per share attributable to common stockholders: | Diluted | 83,424 | 43,931 | 82,344 | 30,190 |

### Income Statement (Three Months Ended June 30, — Reconciliation of GAAP to Non-GAAP Financial Measures:)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| GAAP gross profit | 183,949 | 97,763 | 338,182 | 197,996 |
| GAAP gross margin | 86 | 70 | 86 | 75 |
| Non-GAAP adjustments: | Stock-based compensation expense (1) | 1,128 | 16,441 | 1,965 | 16,441 |
| Non-GAAP adjustments: | Employer payroll tax expense related to stock-based compensation | 45 | 893 | 150 | 893 |
| Non-GAAP adjustments: | Amortization of intangible assets | 224 | 225 | 449 | 406 |
| Non-GAAP adjustments: | Non-GAAP gross profit | 185,346 | 115,322 | 340,746 | 215,736 |
| Non-GAAP adjustments: | Non-GAAP gross margin | 87 | 83 | 86 | 82 |

### Income Statement (Three Months Ended June 30, — Reconciliation of GAAP to Non-GAAP Financial Measures:)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| GAAP income (loss) from operations | 40,440 | -580,671 | 72,509 | -567,535 |
| GAAP operating margin | 19 | -417 | 19 | -216 |
| Non-GAAP adjustments: | Stock-based compensation expense (1) | 19,092 | 590,983 | 30,784 | 590,990 |
| Non-GAAP adjustments: | Employer payroll tax expense related to stock-based compensation | 1,316 | 14,227 | 2,800 | 14,227 |
| Non-GAAP adjustments: | Amortization of intangible assets | 224 | 225 | 449 | 406 |
| Non-GAAP adjustments: | Acquisition-related expenses | 440 | 1,337 | 1,134 | 2,968 |
| Non-GAAP adjustments: | Non-GAAP income from operations | 61,512 | 26,101 | 107,676 | 41,056 |
| Non-GAAP adjustments: | Non-GAAP operating margin | 29 | 19 | 27 | 16 |

### Income Statement (Three Months Ended June 30, — Stock-based compensation expense:)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Cost of revenue | 1,128 | 16,441 | 1,965 | 16,441 |
| Research and development | 7,118 | 248,809 | 10,551 | 248,809 |
| Sales and marketing | 5,965 | 95,050 | 9,969 | 95,050 |
| General and administrative | 4,881 | 230,683 | 8,299 | 230,690 |
| Total stock-based compensation expense | 19,092 | 590,983 | 30,784 | 590,990 |

### Balance Sheet (June 30, 2026 — (in thousands, except par value data))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 286,224 | 207,995 |
| Current assets: | Short-term marketable securities | 103,167 | 155,867 |
| Current assets: | Accounts receivable, net of allowance for credit losses of $6,706 and $6,092 as of June 30, 2026 and December 31, 2025, respectively | 125,432 | 66,061 |
| Current assets: | Deferred commissions | 43,440 | 31,344 |
| Current assets: | Inventory | 16,769 | 15,636 |
| Current assets: | Prepaid expenses and other current assets | 68,321 | 57,001 |
| Current assets: | Total current assets | 643,353 | 533,904 |
| Current assets: | Long-term marketable securities | 84,742 | 113,172 |
| Current assets: | Goodwill | 64,096 | 64,096 |
| Current assets: | Intangible assets, net | 2,063 | 2,512 |
| Current assets: | Property, equipment and software, net | 12,745 | 10,490 |
| Current assets: | Operating lease right-of-use assets | 5,027 | 6,861 |
| Current assets: | Other assets | 15,372 | 13,726 |
| Current assets: | Total assets | 827,398 | 744,761 |
| Current liabilities: | Accounts payable and accrued liabilities | 60,719 | 57,331 |
| Current liabilities: | Operating lease liabilities | 4,254 | 4,223 |
| Current liabilities: | Deferred revenue | 416,466 | 300,855 |
| Current liabilities: | Total current liabilities | 481,439 | 362,409 |
| Current liabilities: | Operating lease liabilities, noncurrent | 1,631 | 3,816 |
| Current liabilities: | Total liabilities | 483,070 | 366,225 |

### Cash Flow (Three Months Ended June 30, — (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Operating activities: | Net income (loss) | 43,690 | -575,651 | 78,818 | -558,512 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | Depreciation and amortization | 1,061 | 1,343 | 2,234 | 2,646 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | Stock-based compensation | 19,092 | 590,983 | 30,784 | 590,990 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | Amortization of deferred commissions | 19,085 | 10,680 | 35,290 | 19,870 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | Accretion of discounts and amortization of premiums on marketable securities, net | 569 | 277 | 704 | 326 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | Non-cash operating lease expense | 929 | 843 | 1,834 | 1,688 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | Provision for credit losses | 1,613 | 1,894 | 1,613 | 2,780 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | Deferred income taxes | 13 | 90 | 13 | 96 |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | Other | -1 | 2 | -1 | -2 |
| Changes in operating assets and liabilities: | Accounts receivable | -12,124 | -25,304 | -60,984 | -59,584 |
| Changes in operating assets and liabilities: | Deferred commissions | -28,476 | -17,020 | -49,079 | -27,650 |
| Changes in operating assets and liabilities: | Inventory | -2,602 | -1,202 | -1,132 | -3,114 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current assets | -7,730 | -14,743 | -11,320 | -6,609 |
| Changes in operating assets and liabilities: | Other assets | 331 | -211 | -327 | -485 |
| Changes in operating assets and liabilities: | Accounts payable and accrued liabilities | -8,654 | -8,713 | 2,592 | 6,997 |
| Changes in operating assets and liabilities: | Operating lease liabilities | -1,084 | -851 | -2,154 | -1,792 |
| Changes in operating assets and liabilities: | Deferred revenue | 75,701 | 57,810 | 115,611 | 57,505 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 101,413 | 20,227 | 144,496 | 25,150 |
| Investing activities: | Purchase of property and equipment | -123 | -197 | -206 | -248 |
| Investing activities: | Capitalized internal use software | -1,731 | -1,630 | -3,178 | -2,336 |
| Investing activities: | Purchases of marketable securities | -30,921 | -85,110 | -89,877 | -175,282 |
| Investing activities: | Maturities of marketable securities | 61,393 | 90,958 | 169,960 | 164,556 |
| Investing activities: | Acquisition of a business |  |  |  | -4,000 |
| Investing activities: | Net cash provided by (used in) investing activities | 28,618 | 4,021 | 76,699 | -17,310 |
| Financing activities: | Proceeds from exercise of common stock options | 270 | 159 | 680 | 256 |
| Financing activities: | Issuance of common stock in connection with the employee stock purchase plan | 7,276 |  | 7,276 |  |
| Financing activities: | Proceeds from issuance of common stock in initial public offering, net of issuance costs |  | 255,675 |  | 255,675 |
| Financing activities: | Repurchase and retirement of common stock | -26,525 |  | -131,491 |  |
| Financing activities: | Tax withholdings on settlement of restricted stock units and performance-based restricted stock units | -11,499 | -272,258 | -19,791 | -272,258 |
| Financing activities: | Payment on Repurchase Agreement with Coatue |  | -50,000 |  | -50,000 |
| Financing activities: | Proceeds from repayment of non-recourse loans to employees |  |  |  | 4,934 |
| Financing activities: | Payments for deferred offering costs |  | -9,134 |  | -10,061 |
| Financing activities: | Net cash used in financing activities | -30,478 | -75,558 | -143,326 | -71,454 |
| Financing activities: | Net increase (decrease) in cash, cash equivalents and restricted cash | 99,553 | -51,310 | 77,869 | -63,614 |
| Financing activities: | Cash, cash equivalents, and restricted cash, beginning of period | 188,112 | 290,282 | 209,796 | 302,586 |
| Financing activities: | Cash, cash equivalents, and restricted cash, end of period | 287,665 | 238,972 | 287,665 | 238,972 |
| Reconciliation of cash, cash equivalents, and restricted cash to the unaudited condensed consolidated balance sheets: | Cash and cash equivalents | 286,224 | 237,170 | 286,224 | 237,170 |
| Reconciliation of cash, cash equivalents, and restricted cash to the unaudited condensed consolidated balance sheets: | Restricted cash | 1,441 | 1,802 | 1,441 | 1,802 |
| Reconciliation of cash, cash equivalents, and restricted cash to the unaudited condensed consolidated balance sheets: | Total cash, cash equivalents, and restricted cash | 287,665 | 238,972 | 287,665 | 238,972 |

### Cash Flow (Three Months Ended June 30, — (in thousands, except percentages))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net cash provided by operating activities | 101,413 | 20,227 | 144,496 | 25,150 |
| Operating cash flow margin | 48 | 15.0% | 37 | 10.0% |
| Adjustment for employer taxes related to pre-IPO stock-based compensation |  | 14,227 |  | 14,227 |
